0000000000067054

AUTHOR

Alexander M.m. Eggermont

showing 11 related works from this author

Curbing tobacco's toll starts with the professionals: World No Tobacco Day

2005

Economic growthbiologyHealth PersonnelTollPolitical scienceRolebiology.proteinHumansSmoking PreventionHealth FacilitiesHealth PromotionGeneral MedicineWorld Health OrganizationThe Lancet
researchProduct

Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial

2000

The ELISPOT assay is increasingly being used for the monitoring of the induction of antigen-reactive T cells in cancer vaccination trials. In order to evaluate the reliability of T cell frequency analysis with the ELISPOT assay, a comparative study was performed in four European laboratories. Six samples from healthy subjects were analyzed for the frequency of influenza-reactive CD8+ T cells in peripheral blood mononuclear cells (PBMC) by IFNgamma-ELISPOT assay. In addition, one laboratory determined cytotoxic T cell precursor (CTL) frequencies in these samples by limiting dilution chromium-release assay (LDA), and three laboratories performed a variant of the LDA, the multiple microculture…

T cellImmunologyEpitopes T-LymphocyteIndicator Dilution TechniquesEnzyme-Linked Immunosorbent AssayCD8-Positive T-LymphocytesLymphocyte ActivationPeripheral blood mononuclear cellViral Matrix ProteinsInterferon-gammaAntigenHLA-A2 AntigenHumansImmunology and AllergyCytotoxic T cellMedicineAntigens ViralImmunodominant Epitopesbusiness.industryELISPOTMolecular biologyChromium RadioisotopesHIV Reverse TranscriptasePeptide FragmentsCTL*medicine.anatomical_structureImmunologyLeukocytes MononuclearCancer vaccinebusinessCD8T-Lymphocytes Cytotoxic
researchProduct

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

2016

The European Society for Medical Oncology (ESMO) is one of the leading societies of oncology professionals in the world. Approximately 30% of the 13 000 ESMO members are below the age of 40 and thus meet the society's definition of young oncologists (YOs). ESMO has identified the training and development of YOs as a priority and has therefore established a comprehensive career development programme. This includes a leadership development programme to help identify and develop the future leaders in oncology. Well-trained and highly motivated future generations of multidisciplinary oncologists are essential to ensure the optimal evolution of the field of oncology with the ultimate goal of pro…

Oncologymedicine.medical_specialtyCancer ResearchReviewFellowshipExecutive boardMultidisciplinary approachInternal medicineJournal ArticleMedicine15061507Leadership developmentbusiness.industryLeadership ProgrammeGénéralitésESMOTraining and developmentYoung OncologistsOncologyESMO; Fellowship; Leadership Programme; Preceptorship; Young OncologistsPreceptorshipPortfoliobusinessCareer developmentESMO; Fellowship; Leadership Programme; Preceptorship; Young Oncologists; Cancer Research; Oncology
researchProduct

Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.

2005

Abstract Quantitative evaluation of T cell responses of patients receiving antitumoral vaccination with a protein is difficult because of the large number of possible HLA-peptide combinations that could be targeted by the response. To evaluate the responses of patients vaccinated with protein MAGE-3, we have developed an approach that involves overnight stimulation of blood T cells with autologous dendritic cells loaded with the protein, sorting by flow cytometry of the T cells that produce IFN-γ, cloning of these cells, and evaluation of the number of T cell clones that secrete IFN-γ upon stimulation with the Ag. An important criterion is that T cell clones must recognize not only stimulat…

CD4-Positive T-Lymphocytesmedicine.medical_treatmentT cellImmunologyAntigen presentationMolecular Sequence DataCD4 T cellsCell SeparationBiologyLymphocyte ActivationCancer VaccinesFlow cytometryInterleukin 21Interferon-gammaAntigenSDG 3 - Good Health and Well-beingAntigens NeoplasmMonitoring ImmunologicmedicineTumor Cells CulturedImmunology and AllergyHumansAmino Acid SequenceLymphocyte CountMelanomaCell Line TransformedAntigen Presentationmedicine.diagnostic_testT-cell receptorCoculture TechniquesGrowth InhibitorsClone CellsNeoplasm Proteinsmedicine.anatomical_structureCell cultureImmunologyAdjuvantVaccineMAGE-3 proteinJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Classification of current anticancer immunotherapies.

2014

© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

immunostimulatory cytokinesmedicine.medical_treatmentReviewBioinformaticsDNA-based vaccinesEfficacy0302 clinical medicineCancer immunotherapyNeoplasmspeptide-based vaccines0303 health sciencesPatología//purl.org/becyt/ford/3.1 [https]CANCER3. Good healthMedicina BásicaOncologycheckpoint blockers030220 oncology & carcinogenesisQR180//purl.org/becyt/ford/3 [https]ImmunotherapyCIENCIAS MÉDICAS Y DE LA SALUDmedicine.drug_classInmunologíaadoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonistsMonoclonal antibodydendritic cell-based interventionsToll-like receptor agonistsRC025403 medical and health sciencesImmune systemAntigen[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologyadoptive cell transfer030304 developmental biologyIMMUNOTHERAPIESbusiness.industryCancerImmunotherapymedicine.diseaseR1Oncolytic virusoncolytic virusesImmunologybusinessOncotarget
researchProduct

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

2020

International audience; Intestinal microbiota have been proposed to induce commensal-specific memory T cells that cross-react with tumor-associated antigens. We identified major histocompatibility complex (MHC) class I-binding epitopes in the tail length tape measure protein (TMP) of a prophage found in the genome of the bacteriophage Enterococcus hirae Mice bearing E. hirae harboring this prophage mounted a TMP-specific H-2Kb-restricted CD8+ T lymphocyte response upon immunotherapy with cyclophosphamide or anti-PD-1 antibodies. Administration of bacterial strains engineered to express the TMP epitope improved immunotherapy in mice. In renal and lung cancer patients, the presence of the ent…

H-2 AntigenProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesEpitopeEpitopesFecesMice0302 clinical medicineEnterococcus hiraeNeoplasmsMonoclonalBacteriophages0303 health sciencesMultidisciplinarybiologyAntibodies MonoclonalViral Tail ProteinsAlkylating3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisCross ReactionEpitopeImmunotherapyHumanT cellAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerCross ReactionsMajor histocompatibility complexAntibodiesMicrobiology03 medical and health sciencesAnimals; Antibodies Monoclonal; Antigens Neoplasm; Antineoplastic Agents Alkylating; Bacteriophages; CD8-Positive T-Lymphocytes; Cross Reactions; Cyclophosphamide; Enterococcus hirae; Epitopes; Feces; Gastrointestinal Microbiome; H-2 Antigens; Histocompatibility Antigens Class I; Humans; Immunotherapy; Mice; Neoplasms; Programmed Cell Death 1 Receptor; Viral Tail Proteins[SDV.CAN] Life Sciences [q-bio]/CancerAntigenAntigens NeoplasmMHC class ImedicineAnimalsHumansAntigensBacteriophageAntineoplastic Agents AlkylatingCyclophosphamideProphage030304 developmental biologyEnterococcus hiraeAnimalHistocompatibility Antigens Class IH-2 AntigensCD8-Positive T-Lymphocytebiology.organism_classificationGastrointestinal Microbiomebiology.proteinNeoplasmFeceCD8
researchProduct

Need for global action for cancer control.

2008

Malemedicine.medical_specialtyCancer ResearchInternational CooperationUterine cervix cancerDiseaseGlobal HealthWorld health03 medical and health sciences0302 clinical medicineCancer controlSDG 3 - Good Health and Well-beingNeoplasmsCancer screeningmedicineGlobal healthHumans030212 general & internal medicineGynecologyHealth Services Needs and DemandCancer preventionbusiness.industryHematologyPrimary Prevention/dk/atira/pure/subjectarea/asjc/2700/2730Risk analysis (engineering)Action (philosophy)Oncology030220 oncology & carcinogenesisFemalebusiness/dk/atira/pure/subjectarea/asjc/1300/1306Annals of oncology : official journal of the European Society for Medical Oncology
researchProduct

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients

2016

International audience; Despite effective targeted therapy acting on KIT and PDGFRA tyrosine kinases, gastrointestinal stromal tumors (GIST) escape treatment by acquiring mutations conveying resistance to imatinib mesylate (IM). Following the identification of NKp30-based immunosurveillance of GIST and the off-target effects of IM on NK cell functions, we investigated the predictive value of NKp30 isoforms and NKp30 soluble ligands in blood for the clinical response to IM. The relative expression and the proportions of NKp30 isoforms markedly impacted both event-free and overall survival, in two independent cohorts of metastatic GIST. Phenotypes based on disbalanced NKp30B/NKp30C ratio (Del…

0301 basic medicinemedicine.medical_treatmentImmunologyPDGFRATargeted therapy03 medical and health sciences0302 clinical medicinemedicineImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyneoplasmsOriginal ResearchTumor microenvironmentGiSTbusiness.industryCancermedicine.diseasedigestive system diseases3. Good healthImmunosurveillance030104 developmental biologyImatinib mesylateOncology030220 oncology & carcinogenesisImmunologyCancer research[SDV.IMM]Life Sciences [q-bio]/ImmunologybusinessTyrosine kinase
researchProduct

The Porto European Cancer Research Summit 2021.

2021

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…

Cancer Researchmedicine.medical_specialty:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]infrastructures for translational cancer researchDeclarationTranslational researchContext (language use)comprehensive cancer centresMeeting Reportclinical/prevention trials:profesiones sanitarias::medicina::medicina clínica::medicina de precisión [DISCIPLINAS Y OCUPACIONES]Translational Research Biomedicaloutcomes research:neoplasias [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]cancer research/care/prevention continuumNeoplasmsPolitical scienceGeneticsmedicineHumansmedia_common.cataloged_instance:Health Occupations::Medicine::Clinical Medicine::Precision Medicine [DISCIPLINES AND OCCUPATIONS]Medicina personalitzadaPrecision MedicineEuropean unionRC254-282media_commongeographySummitgeography.geographical_feature_categoryHealth economics:Natural Science Disciplines::Science::Research::Biomedical Research [DISCIPLINES AND OCCUPATIONS]Neoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineCancer MissionEuropescience policy:Neoplasms [DISEASES]Medicina - InvestigacióOncologyQuality of LifeCancer researchMolecular MedicineScience policyCàncer - PrevencióOutcomes research:disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica [DISCIPLINAS Y OCUPACIONES]
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Tobacco: deadly in any form or disguise

2006

AdultMaleAdolescentbusiness.industrySmoking preventionSmokingMEDLINESmoking PreventionHealth PromotionGeneral MedicineMiddle AgedGlobal HealthHealth promotionEnvironmental healthTobaccoGlobal healthHumansMedicineFemaleMortalityChildbusinessAgedThe Lancet
researchProduct